Literature DB >> 12084461

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.

G J Peters1, H H J Backus, S Freemantle, B van Triest, G Codacci-Pisanelli, C L van der Wilt, K Smid, J Lunec, A H Calvert, S Marsh, H L McLeod, E Bloemena, S Meijer, G Jansen, C J van Groeningen, H M Pinedo.   

Abstract

Thymidylate synthase (TS) is a key enzyme in the de novo synthesis of 2'-deoxythymidine-5'-monophosphate (dTMP) from 2'-deoxyuridine-5'-monophosphate (dUMP), for which 5,10-methylene-tetrahydrofolate (CH(2)-THF) is the methyl donor. TS is an important target for chemotherapy; it is inhibited by folate and nucleotide analogs, such as by 5-fluoro-dUMP (FdUMP), the active metabolite of 5-fluorouracil (5FU). FdUMP forms a relatively stable ternary complex with TS and CH(2)THF, which is further stabilized by leucovorin (LV). 5FU treatment can induce TS expression, which might bypass dTMP depletion. An improved efficacy of 5FU might be achieved by increasing and prolonging TS inhibition, a prevention of dissociation of the ternary complex, and prevention of TS induction. In a panel of 17 colon cancer cells, including several variants with acquired resistance to 5FU, sensitivity was related to TS levels, but exclusion of the resistant variants abolished this relation. For antifolates, polyglutamylation was more important than the intrinsic TS level. Cells with low p53 levels were more sensitive to 5FU and the antifolate raltitrexed (RTX) than cells with high, mutated p53. Free TS protein down-regulates its own translation, but its transcription is regulated by E2F, a cell cycle checkpoint regulator. Together, this results in low TS levels in stationary phase cells. Although cells with a low TS might theoretically be more sensitive to 5FU, the low proliferation rate prevents induction of DNA damage and 5FU toxicity. TS levels were not related to polymorphisms of the TS promoter. Treatment with 5FU or RTX rapidly induced TS levels two- to five-fold. In animal models, 5FU treatment resulted in TS inhibition followed by a two- to three-fold TS induction. Both LV and a high dose of 5FU not only enhanced TS inhibition, but also prevented TS induction and increased the antitumor effect. In patients, TS levels as determined by enzyme activity assays, immunohistochemistry and mRNA expression, were related to a response to 5FU. 5FU treatment initially decreased TS levels, but this was followed by an induction, as seen with an increased ratio of TS protein over TS-mRNA. The clear retrospective relation between TS levels and response now forms the basis for a prospective study, in which TS levels are measured before treatment in order to determine the treatment protocol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12084461     DOI: 10.1016/s0925-4439(02)00082-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  107 in total

1.  TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; M J E M Gosens; E Moerland; I van Lijnschoten; V E P P Lemmens; G D Slooter; H J T Rutten; Adriaan J C van den Brule
Journal:  Cell Oncol (Dordr)       Date:  2011-06-01       Impact factor: 6.730

2.  [mRNA quantification. The next challenge in routine diagnostics].

Authors:  A Jung; S Jaitner; A J Schäffauer; T Kirchner
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.

Authors:  Roshawn G Watson; Filipe Muhale; Leigh B Thorne; Jinsheng Yu; Bert H O'Neil; Janelle M Hoskins; Michael O Meyers; Allison M Deal; Joseph G Ibrahim; Michael L Hudson; Christine M Walko; Howard L McLeod; James T Auman
Journal:  Eur J Cancer       Date:  2010-08-18       Impact factor: 9.162

Review 4.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer.

Authors:  Mehdi Manoochehri; Ashraf Karbasi; Mojgan Bandehpour; Bahram Kazemi
Journal:  Pathol Oncol Res       Date:  2013-10-14       Impact factor: 3.201

6.  Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.

Authors:  Sara Nannizzi; Gareth J Veal; Elisa Giovannetti; Valentina Mey; Simona Ricciardi; Christopher J Ottley; Mario Del Tacca; Romano Danesi
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-18       Impact factor: 3.333

Review 7.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

8.  Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.

Authors:  Tian-Li Wang; Luis A Diaz; Katharine Romans; Alberto Bardelli; Saurabh Saha; Gennaro Galizia; Michael Choti; Ross Donehower; Giovanni Parmigiani; Ie-Ming Shih; Christine Iacobuzio-Donahue; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-17       Impact factor: 11.205

9.  Interaction between thymidylate synthase and its cognate mRNA in zebrafish embryos.

Authors:  Yuyan Zhang; Shaoli Yang; Ming Liu; Chunxia Song; Ning Wu; Peixue Ling; Edward Chu; Xiukun Lin
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

10.  Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer.

Authors:  Ebrahim Eftekhar; Fakhraddin Naghibalhossaini
Journal:  Mol Biol Rep       Date:  2013-11-29       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.